Molecular biology of breast cancer
- Miguel Martín
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Although Breast Cancer (BC) has been considered for many years as a single entity with a common management and treatment, it is actually a extremely heterogeneous disease which includes at least 4 or 5 very different subtypes. The first step in the recognition of the heterogeneity of BC was the demonstration of the presence of functional hormonal receptors (HR) in nearly two thirds of breast cancer specimens. This finding, which established a first classification of BC in two clear subtypes (HR-positive and HR-negative) was followed by the demonstration of many other differential features. The her2/neu gene alteration, present in nearly 20% of BC tumors, is probably the most relevant of them, but certainly not the only one. The development of new technologies and, in particular, the use of complementary DNA (cDNA)microarrays will allow us now the simultaneous analysis of thousands of genes and the establishment of new, more refined BC subtypes based on gene expression profiles/genetic fingerprints.
This review discusses the practical applications of molecular analysis of BC, which can be classified in four categories:
Establishment of a new molecular taxonomy of breast cancer.
Definition of prognostic factors/prognostic indexes based on molecular/genetic peculiarities.
Prediction of response to diverse antitumoral treatments.
Identification of molecular targets that allows the development of new tailored antitumor treatments.
- Cristofanilli M, González-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41–8. CrossRef
- Korkola JE, DeVries S, Fridland J, et al. Differentiation of lobular versus ductal breast carcinomas by expression mycroarray analysis. Cancer Res. 2003;63:7167–75.
- National Human Genome Research Institute. National Institutes of Health. http://www.genome.gov/
- Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52. CrossRef
- Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100:8418–23. CrossRef
- Subramaniam D, Isaacs C. Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options in Oncol. 2005;6:147–59. CrossRef
- Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart M. Bringing Molecular Prognosis and Prediction to the Clinic. Clinical Breast Cancer. 2005;6:61–76.
- Janicke F, Smith M, Pache L, et al. Urokinase-type plasminogen (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat, 1993;24:195–208. CrossRef
- Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8577 breast cancer patients. J Natl Cancer Inst. 2002;94: 116–28.
- Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996; 88:1456–66. CrossRef
- Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913–20. CrossRef
- Keryomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002; 347:1566–75. CrossRef
- Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study ofc-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334–56.
- Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene ampliflcation characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894–904.
- Wenger CR, Clark GM. S-phase fraction and breast cancer: a decade of experience. Breast Cancer Res Treat. 1998;51:255–65. CrossRef
- Silvestrini R, Daidone MG, Luisi A, et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol. 1995;13:697–704.
- Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–20. CrossRef
- Knowlton K, Mancini M, Creason S. Morales C, Hockenbwy D, Anderson BO. Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res. 1998;76:22–6. CrossRef
- van Slooten HJ, Clahsen PC, van Dierendonck JH, et al. Expresión of Bcl-2 In node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of peroperative chemotherapy. Br J Cancer. 1996;74:78–85.
- Pharoah PDP, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer. 1999;80:1968–73. CrossRef
- van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6. CrossRef
- van de Vljver M, He YD, van't Veer L, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. CrossRef
- Espinosa E, Fresno Vara JA, Redondo A, et al. Breast cancer prognosis determined by gene expression profiling: A quantitative RT-PCR study. J Clin Oncol. 2005;23: 7278–85. CrossRef
- Wang Y, Klijn JG, Zhang Y, et al. Gene expression profiles to predict distant metastasis of lymph node negative primary breast cancer. Lancet. 2005;365:671–9.
- Ahr A, Kam T, Solbach, C, et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet. 2002; 359:131–2. CrossRef
- Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23: 7721–35. CrossRef
- Harbeck N, Bohlmann I, Ross JS, et al. Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated node-negative breast cancer using paraphine-embedded tumor tissue. J Clin Oncol. 2005;23 Suppl 16:5S (abstract 505).
- Hopp TA, Weiss HL, Hilsenbeck SG, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004;10:2751–60. CrossRef
- Jansen MP, Foekens JA, van Staveren IL, et al. Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. J Clin Oncol. 2005; 23:732–40. CrossRef
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifentreated node-negative breast cancer. N Engl J Med. 2004;351:2817–26. CrossRef
- Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application? J Clin Oncol. 2005; 23:7350–60. CrossRef
- Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3,424). Cancer Res. 2002;62:4617–22.
- Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. PNAS. 2005;102:8315–20. CrossRef
- Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubule-Associated Parameters as Predictive Markers of Docetaxel Activity in Advanced Breast Cancer Patients: Results of a Pilot Study. Clinical Breast Cancer. 2002;3:341–5. CrossRef
- Bautista de Lucio V, Madrid Marina V, Barrera Rodríguez R. The molecular biology of topoisomerase IIalpha and its importance in the acquisiton of multidrug resistance in cancer. Rev Oncol 2002;4: 67–72.
- Durbecq V, Paesmans M, Cardoso F, et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 2004;3:1207–14.
- Knoop AS, Knudsen H, Balslev A, et al. Retrospective Analysis of Topoisomerase IIalpha Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and fluorouracil or Cyclophosphamide, Epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23:7483–90. CrossRef
- Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab, with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treatment 2005;94 Suppl 1:S5 (abstract 1).
- González-Angulo AM, Krishnamurthy S, Yamamura Y, et al. Lack of Association between Amplification of her-2 and Response to Preoperanve taxanes in Patiems with Breast Carcinoma. Cancer. 2004;101:258–63. CrossRef
- Zhang F, Yang Y, Smith T, et al. Correlation between her-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin and cyclo phosphamide in patients with breast carcinoma. Cancer. 2003;97:1758–65. CrossRef
- Ayers M, Symmans WF, Stec J, et al. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer. J Clin Oncol. 2004;22:2284–93. CrossRef
- Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–9. CrossRef
- Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients. J Clin Oncol. 2005;23:1169–77. CrossRef
- Gianni L, Zambetti M, Clark K, et al. Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. J Clin Oncol. 2005;23:7265–77. CrossRef
- Hannemann J, Oosterkamp HM, Bosch CAJ, et al. Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer. J Clin Oncol. 2005;23:3331–42. CrossRef
- Rouzier R, Perou CM, Symmans F, et al. Breast Cancer Molecular Subtypes Respond Differently to Preooerative Chemotherapy. Clin Cancer Res. 2005;11:5678–85. CrossRef
- Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 1999;286:2507–10. CrossRef
- Tammela Enholm B, Alitalo K, Pavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550–63. CrossRef
- Esteller M. CpG island hypermetilation and tumor suppressor geens: a booming present, a brighter future. Oncogene. 2002; 343:1350–4.
- Shay JV, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002; 2:257–65. CrossRef
- Ramírez de Molina A, Gutiérrez R, Ramos MA, et al. Increased cholin kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene. 2002;21:4317–23. CrossRef
- Arnold A, Papanikolau A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215–24. CrossRef
- Aznar S, Lacal JC. Searching for new targets for anticancer drug design: the families of ras and rhoGPTases and their effectors. Prog Nucleic Res Mol Biol. 2001; 67:193–234. CrossRef
- Osborne C, Wilson P, Tripathy D. Oncogeens and tumor supresor genes in brewast cancer: potential diagnostic and therapeutic applications. The Oncologist. 2004;9:361–77. CrossRef
- Massague J. Breast Cancer metastasis genes and functions. Breast Cancer Res Treatment. 2005;94:Suppl 1:S3.
- Molecular biology of breast cancer
Clinical and Translational Oncology
Volume 8, Issue 1 , pp 7-14
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Miguel Martín (1)
- Author Affiliations
- 1. Servicio de Oncología Médica, Hospital Universitario San Carlos, Madrid, Spain